AMENDMENT UNDER 37 C.F.R § 1.111 U.S. Appln. No. 08/860,377

where the [(] symbols in the formula have the following meanings:

Ring A:


- (1) an aryl(aromatic hydrocarbon) group having 6 to 14 carbon atoms
- a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom
- (3) a cycloalkyl group having 3 to 8 carbon atoms
- (4) a gycloakenyl group having-3-to-8 carbon atoms
- (5) a 5- to 7-membered saturated heterocyclic group;

wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfonyl group, a sulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower aklylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxyl group, an amino group or mono- or di-lower alkylamino group

[an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atoms and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, wherein said ring may be substituted by an optional substituent;]

D

90



X: a single bond or a methylene group;

a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower akylsulfonyl group, a sulfinyl group, a lower alkylsufinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

 ℓ : 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2[)],

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof.

Kindly cancel without prejudice claim 2.

Claim 8, next to the last line, delete "and optically active substances thereof".

(Amended) A pharmaceutical composition which comprises a quinuclidine derivative represented by the following formula (I):

$$(R)m = (CH_2)n \qquad (CH_2)n \qquad (I)$$

$$Ring A \qquad -3 \qquad (I)$$

Clubb

R:

9,1

AMENDMENT UNDER 37 C.F.R § 1.111 U.S. Appln. No. 08/860,377

where the [() symbols in the formula have the following meanings:

Ring A:

- (1) an aryl(aromatic-hydrocarbon) group having 6 to 14 carbon atoms
- (2) a heteroaryl group having 1 to 4 hetero atoms selected from the group
 - consisting of an exygen atom, a nitrogen atom and a sulfur atom-
- (3) a cycloalkyl group having 3 to 8 carbon atoms
- (4) a cycloakenyl group having 3 to 8 carbon atoms
- (5) a-5- to 7-membered-saturated heterocyclic group;

wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfonyl group, a sulfinyl group, a carbamoyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxyl group, an amino group or mono- or di-lower alkylamino group

[an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atoms and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, wherein said ring may be substituted by an optional substituent;]

- X: a single bond or a methylene group;
- R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower akylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano

19

AMENDMENT UNDER 37 C.F.R § 1.111 U.S. Appln. No. 08/860,377

Child Child

group, an amino group, a mono- or di-lower alkylamino group, a methylenenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

 ℓ : 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2, or a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof, and a pharmaceutically acceptable carrier.

Please cancel without prejudice claims 12 and 13.

Kindly add following new claim 14.

--14. A method of treating muscarine M₃-related diseases comprising administering a therapeutically effective amount of a quinuclidine derivative or a salt thereof, an N-oxide or a quaternary ammonium salt as claimed in claim 1 as a muscarinic M₃ receptor antagonist to a patient in need of the same.--

REMARKS

Claims 1, 3-9 and 14 are all the claims pending in the application. The amended claims and newly added claim 14 are supported by the disclosure. Hence, entry is respectfully requested.